Testing further confirms Bentrio's broad protection against various types of airborne viruses
Demonstrates significant reductions in viral load for preventive and mitigative treatment after 4 days vs. saline controls
HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced positive outcomes from testing Bentrio™ for protection in human rhinovirus (HRV) infection. Bentrio is a drug-free nasal spray developed and commercialized by the Company's affiliate Altamira Medica for protection against airborne viruses and allergens.
Bentrio was tested for its capability to prevent or mitigate infection of the human nasal epithelium by HRV (RV-16A). For the experiment, reconstituted cells from donors were inoculated with the virus either 10 minutes after the first application of Bentrio (to test the formulation's preventive effects) or 12 hours prior to the first application of Bentrio (to test the formulation's mitigative effects). Bentrio was applied daily for four days; the viral load (Tissue Culture Infectious Dose, TCID50) was determined on MDCK cell lines. Prophylactic treatment with Bentrio resulted in a statistically significant reduction in the viral load vs. saline controls at Day 4 (p<0.05, two-way ANOVA), whereas mitigative treatment showed statistically significant reductions at both Day 3 and Day 4 (p<0.05 and p<0.01, respectively). On Day 4, the viral load was 89.5% and 98.9%, respectively, lower than in controls.
"These latest in vitro results obtained in human rhinovirus infection fit nicely with our previous data in SARS-CoV-2 and H1N1 infections, thus further confirming Bentrio's broad protection against various types of airborne viruses," commented Thomas Meyer, Altamira Therapeutic's founder, Chairman and CEO. "We see a great potential for Bentrio as a versatile nasal spray that is easy to use, affordable and helps to protect against the myriad of pathogens and allergens to which we are exposed in our daily lives by breathing in air."
Human rhinovirus (HRV) is the most common cause of the common cold but may also lead to more severe respiratory illness in vulnerable populations such as people with weakened immune systems, asthma, or respiratory conditions. According to the US Centers for Disease Control and Prevention, each year in the United States, there are millions of cases of the common cold. Adults have an average of 2-3 colds per year, and children have even more. Most people get colds in the winter and spring, but it is possible to get a cold any time of the year. Medications for "Cough and cold" represent one of the most important "Over the counter" product categories.
Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. For more info, visit:
Bentrio is being distributed in selected European countries and is expected to become available through distributors in further countries in Europe, Asia and MENA. In the US, Altamira submitted a 510(k) application of Bentrio in the treatment of allergic rhinitis, which is currently under review by the FDA.
About Altamira Therapeutics
Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: altamiratherapeutics.com/.
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
SOURCE: Altamira Therapeutics